VTGN Live signals | Maximize Profits with Getagraph.com

SELL 93783 min ago

@ $5.09

Issued: 14 Feb 2024 @ 09:30

Return: -7.47%

Previous signal: Feb 12 - 13:37

Previous signal: Buy

Return: -0.97 %

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 13:30):

Stats
Today's Volume	49 074.00
Average Volume	268 941
Market Cap	127.29M
EPS	$0 ( 2024-02-13 )
Next earnings date	( $-0.340 ) 2024-06-26
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.590
ATR14	$0.0130 (0.28%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-04	Rotunno Mary L.	Buy	12 500	Stock Option (Right to Buy)
2024-03-04	Gin Jerry B	Buy	12 500	Stock Option (Right to Buy)
2024-03-04	Fitzpatrick Margaret M	Buy	12 500	Stock Option (Right to Buy)
2024-03-04	Curley Joanne	Buy	12 500	Stock Option (Right to Buy)
2024-03-04	Cunningham Ann Michelle	Buy	12 500	Stock Option (Right to Buy)

INSIDER POWER
98.34
Last 94 transactions
Buy: 11 348 392 \| Sell: 716 774

Volume Correlation

Long: -0.03 (neutral)

Short: 0.00 (neutral)

Signal:(45.568) Neutral

VistaGen Therapeutics Inc Correlation

10 Most Positive Correlations
ADXN	0.836
SHYF	0.828
SRRK	0.827
FLUX	0.822
PRAX	0.821
LILAK	0.819
LILA	0.816
PXLW	0.816
TNXP	0.816
FOXA	0.805

10 Most Negative Correlations
FEYE	-0.808

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

VistaGen Therapeutics Inc Correlation - Currency/Commodity

0.75
( moderate )

0.69
( moderate )

0.00
( neutral )

0.73
( moderate )

-0.21
( neutral )

-0.77
( moderate negative )

VistaGen Therapeutics Inc Financials

Annual	2023
Revenue:	$-227 300
Gross Profit:	$-737 100 (324.29 %)
EPS:	$-8.51

Q4	2023
Revenue:	$175 600
Gross Profit:	$22 000.00 (12.53 %)
EPS:	$-1.710

Q3	2023
Revenue:	$179 600
Gross Profit:	$47 400.00 (26.39 %)
EPS:	$-1.420

Q2	2023
Revenue:	$-892 500
Gross Profit:	$-1.03M (114.86 %)
EPS:	$-2.54

Financial Reports:

No articles found.

VistaGen Therapeutics Inc

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.